Anti-Lymphoma Monoclonal Antibodies: Making Better Antibodies and Making Antibodies Better.
Monoclonal antibodies (mAbs) are highly effective anti-cancer agents; however, there is still considerable room for improving their therapeutic impact. Understanding the mechanisms of action of anti-cancer mAbs, and modifying mAb structure based on this understanding, is leading to the design and testing of more effective mAbs.
Iowa City, Iowa.
George J
GJ
Weiner
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000918:Antibody Specificity; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D055808:Drug Discovery; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D008223:Lymphoma / Q000188:drug therapy* / Q000276:immunology; D058990:Molecular Targeted Therapy; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents